Cytos Biotechnology Ltd. is renamed Kuros Biosciences Ltd.

Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd.

21-Jan-2016 - Kuros Biosciences Ltd. announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all 508'432'244 Kuros Biosciences Ltd. shares are listed and freely tradable under the ticker symbol ...

Cytos Biotechnology and Kuros Biosurgery to combine

04-Dec-2015 - Cytos Biotechnology Ltd. and Kuros Biosurgery Holding AG, announced their intention to combine their businesses by way of an exchange of Kuros shares for new Cytos shares, subject to shareholder approval and other customary conditions. The combined entity will operate under the name "Kuros ...

Kuros and Synthes Inc. announce license and development agreement

20-Mar-2012 - Kuros Biosurgery AG has signed a license and development agreement with Synthes, Inc.. Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros’ synthetic matrix technology in certain fields.Commenting on today’s announcement, Mr. Didier Cowling, CEO of Kuros, ...

KUROS Announces allowance of US Patent For the local application of Parathyroid hormone (PTH) for bone healing

20-Jul-2011 - Kuros Biosurgery AG announced that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office. The now allowed application acknowledges that Kuros has been first in showing that parathyroid hormone (PTH) when applied locally in a matrix to a bone defect has the ability to ...

KUROS announces allowance of European Patent for synthetic biomaterials

21-Jun-2011 - Kuros Biosurgery AG announced the allowance of European Patent Application 00910049 by the European Patent Office. This now allowed patent application is a key component of a broad portfolio of applications and patents designed to protect Kuros’ synthetic biomaterial (matrix) technologies and its ...

Kuros meets primary endpoint in Phase IIb trial of KUR-113 in patients with open tibial shaft fractures

Second successful Phase IIb study in bone repair indications highlights the potential of Kuros “TG Hook” Technology

27-Apr-2011 - Kuros Biosurgery AG announced that KUR-113 (Viz.I-040202) met the primary efficacy endpoint in a 200 patient Phase IIb clinical trial designed to assess its efficacy and safety in open tibial shaft fracture patients. The primary endpoint of the study is the proportion of patients healed at 6 ...

Kuros treats first patient with dural sealant product candidate KUR-023

European study is first clinical assessment of Kuros' proprietary synthetic technology

02-Mar-2011 - Kuros Biosurgery AG announced that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.KUR-023 is a synthetic hydrogel-based sealant that utilises Kuros' synthetic technology. The product candidate ...

Kuros completes patient recruitment in a phase IIb trial of KUR-113 in patients with tibial shaft fractures

02-Jun-2010 - Kuros Biosurgery AG announced that it has completed recruitment in a 200 patient Phase IIb clinical trial designed to assess the efficacy and safety of KUR-113 (Viz.I-040202) in open tibial shaft fractures. This study is a randomized, controlled, open-label (dose-blinded) dose finding study of ...

Kuros meets primary efficacy endpoint in Phase IIb study with KUR-111

15-Mar-2010 - Kuros Biosurgery AG announced the results of a Phase IIb clinical trial assessing the potential of KUR-111 (Viz.I-0401) in the treatment of patients with tibial plateau fractures that require fixation and grafting. The study achieved its primary efficacy endpoint, which was the demonstration of ...

KUROS Announces Encouraging phase IIa DATA WITH KUR-212 In Patients with Burns requiring Mesh Grafting

12-Aug-2009 - Kuros Biosurgery AG announced the final results of a Phase IIa clinical trial assessing the potential of KUR-212 (Viz.I-020502) in the treatment of burn patients that require autologous (from the patient) meshed skin grafting. KUR-212 is a combination product based on fibrin and a variant of ...